CD79A and COVID-19: Anti-N+, PCR(−): Participants who were already seropositive for anti-N IgG/IgA antibodies upon initial sample collection with no prior history of COVID-19-related symptoms or PCR/RAT-confirmed SARS-CoV-2 infections.